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Abstract
Purpose—To assess acute and late adverse events (AEs), overall survival (OS), pelvic failure
(PF), regional failure, distant failure, and disease-free survival (DFS) in a prospective phase II
clinical trial of bevacizumab (Bev) and pelvic intensity modulated radiation therapy (IMRT) with
chemotherapy in high-risk endometrial-cancer patients.
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Materials/Methods—Patients had a hysterectomy, lymph node removal, and ≥1 of the
following high-risk factors: grade 3 carcinoma with >50% myometrial invasion; grade 2 or 3
disease with any cervical stromal invasion; or known extrauterine extension confined to the pelvis.
Treatment included pelvic IMRT and concurrent cisplatin on days 1 and 29 of radiation and Bev
(5 mg/kg on days 1, 15 and 29 of radiation) followed by adjuvant carboplatin and paclitaxel for 4
cycles. The primary endpoint was grade ≥3 AEs in the first 90 days.
Results—Thirty-four patients were accrued from November 2009 through December 2011, 30 of
whom were eligible and received study treatment. Seven out of 30 patients (23.3%, 90% CI:
10.6%-36.0%) had grade ≥3 treatment-related non-hematologic toxicities within 90 days; an
additional 6 patients had grade ≥3 toxicities between 90 and 365 days after treatment. Two-year
OS was 96.7% and DFS was 79.1%. No patient developed a within-field PF and no patients with
stage I-IIIA disease relapsed after a median follow-up of 26 months.

Author Manuscript

Conclusion—Postoperative Bev added to chemotherapy and pelvic IMRT is well tolerated and
results in high overall survival rates at 2 years for patients with high-risk endometrial carcinoma.

INTRODUCTION

Author Manuscript

Endometrial cancer is the most common cancer of the female reproductive organs in the
United States. Over 50,000 women are diagnosed annually, with the majority presenting
with early-stage disease curable by surgery alone.1 Nevertheless, more than 8,000 women
die of the disease each year due to a combination of local and distant failures.1 Prior studies
have indicated that pelvic external beam radiation may reduce the risk of local recurrence in
high-risk patients, while chemotherapy may decrease the risk of distant metastasis. In the
Gynecologic Oncology Group (GOG) randomized trial, chemotherapy was associated with
reduced distant metastases (22 vs. 18%) in stage III/IV patients,2 but not in stage I/II
patients.3 The Radiation Therapy Oncology Group (RTOG) 9708 phase II clinical trial
treated women with high-risk endometrial cancer with pelvic radiation and concurrent
cisplatin, followed by additional cisplatin and paclitaxel chemotherapy. Results showed a
low rate of local recurrence (2%), but a high rate of distant metastases (19%).4 Given these
and other findings, it was postulated that the addition of bevacizumab (Bev), an antiangiogenic agent, may further reduce the risk of distant metastases. With prior trials
demonstrating the feasibility of using pelvic intensity modulated radiation therapy (IMRT)
in postoperative patients,5 IMRT was chosen in the hope of reducing the incidence or
severity of bowel toxicity, which might be exacerbated by Bev.

Author Manuscript

The primary objective of this trial was to assess the rates of grade ≥3, non-hematologic,
treatment-related adverse events (AEs) within 90 days from the start of treatment when
administering concurrent Bev, cisplatin, and IMRT followed by carboplatin and paclitaxel
chemotherapy in patients with high-risk endometrial cancer. The secondary objectives were
to evaluate treatment-related AEs occurring within one year from start of treatment; all
treatment-related AEs; disease-free and overall survival (DFS, OS); and local, regional and
distant failure. Two-year efficacy rates are reported.
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MATERIALS AND METHODS
Eligibility requirements for RTOG 0921

Author Manuscript

A hysterectomy and bilateral salpingo-oophorectomy must have been completed within 56
days prior to study entry with pathologic confirmation of uterine cancer meeting one or
more of the following criteria: grade 3 carcinoma with >50% myometrial invasion (all
papillary serous and clear cell carcinomas were considered grade 3); grade 2 or 3 carcinoma
with any cervical stromal invasion; or known extra-uterine disease confined to the pelvis,
any grade. The following histologies were allowed: endometrioid endometrial
adenocarcinoma, clear cell carcinoma, papillary serous adenocarcinoma, adenosquamous
carcinoma or other adenocarcinoma variant. All patients had Zubrod performance status 0-1,
were ≥18 years of age, and were able to sign a study-specific informed consent. Patients
must have had adequate bone marrow, renal and hepatic function as indicated by the
following laboratory assessments within 21 days prior to study entry: ANC ≥1500 cells/mm3
without use of growth factors; platelets ≥100,000/mm3; serum creatinine ≤1.5 mg/dl; total
bilirubin ≤1.5 times institutional upper normal limit; hemoglobin ≥10 g/dl (transfusion may
have been used to meet this criterion); AST and ALT ≤2 times institutional upper normal
limit; INR <1.5 for patients treated with warfarin within 14 days prior to study entry; urine
protein creatinine (UPC) ratio (if UPC ratio >0.5, 24-hour urine protein should be obtained
and should be <1000 mg for patient enrollment) ; in patients with FIGO stage III or IVA
disease, CT or PET-CT of the abdomen and pelvis was required within 56 days of study
entry. To assess the chest for all patients regardless of stage, a chest x-ray or chest CT or
PET-CT was required within 56 days of study entry.
Treatment

Author Manuscript

No sooner than 29 days and no later than 56 days after surgery, patients began a course of
IMRT with concurrent cisplatin (50 mg/m2 on days 1 and 29 of radiation) and Bev (5 mg/kg
on days 1, 15 and 29 of radiation) followed by an optional boost with either high-dose-rate
(HDR, 6 Gy for 3 fractions) or low-dose-rate (LDR, 25 Gy at 0.8-1.2 Gy per hour) vaginal
brachytherapy. This was followed by 4 cycles of carboplatin (AUC 5) and paclitaxel (135
mg/m2).
Full- and empty-bladder CT scans were required and were fused together prior to outlining
target volumes. Contours were recommended to follow the RTOG IMRT for postoperative
endometrial and cervical cancer guideline atlas6 and underwent central review with
corrections recommended prior to initiating treatment.

Author Manuscript

The vaginal planning target volume (PTV) (integrated target volume with a 7-mm margin)
and nodal PTV (nodal CTV with a 7-mm margin) were prescribed 45 Gy in 25 fractions.
The dose was prescribed to cover 97% of the vaginal PTV and nodal PTV. Bone-marrow
sparing with IMRT was not required and no bone dose-volume constraints were
implemented as part of this protocol. Patients with pelvic lymph node(s) ≥2 cm in any
dimension on the diagnostic or planning CT or biopsy-proven to be positive were candidates
to receive, at the discretion of the treating radiation oncologist, 8 additional fractions to the
enlarged node(s) in 1.8-Gy daily fractions for a total dose of 59.4 Gy to the nodal boost
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PTV. Patients were followed for disease status with history and physical examination every
3 months for 1 year, every 6 months for another 2 years, and annually thereafter.
Statistical analysis
Primary endpoint—Given that the rate of acute grade ≥3 non-hematologic treatmentrelated AEs from RTOG 9708 (RT + cisplatin) was 44%, the hypothesis for the current trial
was that the addition of Bev to IMRT + cisplatin would not increase this rate beyond 60%.
This study was designed with a 1-sided, upper-bound confidence interval to estimate this AE
rate. Twenty-seven evaluable patients were required to have 95% confidence that the true
grade ≥3, non-hematologic, treatment-related AE rate is not greater than 60%. To allow for
ineligible/non-protocol treatment patients, a total sample size of 34 patients was required for
this study. AEs were scored according to the National Cancer Institute Common
Terminology Criteria for AEs, version 4.0 (MedDRA version 12.0).

Author Manuscript
Author Manuscript

Secondary endpoints—For overall survival (OS), failure was defined as death due to
any cause and survival time was measured from date of study entry to death or last followup for non-failures. Data for living patients were censored at the date of last contact. Pelvic
failure (PF) was defined as recurrence in the pelvis, including the pelvic or sacral nodes, and
required confirmation by histologic or cytologic biopsy of the recurrent lesion. Regional
failure (RF) was defined as recurrence in the para-aortic nodal region. Distant failure (DF)
was defined as the appearance of distant metastasis. Death was considered a competing risk
for PF, RF, and DF and each were measured from date of study entry to date of first failure
or last follow-up for non-failures. For disease-free survival (DFS), failure was defined as PF,
DF, or death due to any cause and was measured from date of study entry to date of first
failure or last follow-up for non-failures. OS and DFS were estimated univariately with the
Kaplan-Meier method7 and PF, RF, and DF rates were estimated using the cumulative
incidence method.8

RESULTS
A total of 34 patients were accrued from November 6, 2009 until December 12, 2011. Four
patients were excluded from analysis: 1 did not receive protocol treatment and 3 were
ineligible (1 had a PET/CT scan >56 days prior to study registration, 1 had positive
peritoneal cytology, and 1 had urinary protein creatinine >1). Detailed baseline patient
characteristics of the 30 patients included in the analysis are listed in Table 1. A total of 29
of 30 patients underwent bilateral pelvic lymph node dissection and 19 had para-aortic
lymph node removal.

Author Manuscript

Protocol Treatment Compliance
A total of 93% of patients were treated per protocol with concurrent chemotherapy and 90%
received their adjuvant chemotherapy per protocol. All patients received Bev in full and on
time.
Radiation treatment compliance was assessed in terms of whether physician contours of the
tumor volume and organs at risk, which underwent rapid review within 24 hours, followed
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the protocol-recommended contouring guidelines. For tumor-volume contouring, 23 were
per protocol and 7 (23%) had an acceptable variation.
For organs-at-risk contouring, 27 patients were considered per protocol while 3 (10%) had
acceptable variations. Bladder, sigmoid, femur and tumor volume were all contoured per
protocol on final submission (after rapid review for institutional first case). Barium contrast
given by mouth to opacify the small bowel was allowed at the physician's discretion. Two
patients (6.7%) had unacceptable deviations on small-bowel contouring, where the bowel
loops were contoured instead of the bowel space; in the other 28 cases, the small bowel was
contoured per protocol. One patient had an acceptable variation on rectum contouring, with
the inferior portion of the rectal contour overlapping the vaginal integrated target volume
(ITV); the other 29 rectal contours were per protocol.

Author Manuscript

Compliance was also assessed with regard to treatment planning, with assessments of
whether the nodal and vaginal PTV, bladder, rectum, femoral heads and bowel planned
doses met the protocol set dose limits. With regard to treatment planning, 5 cases had
‘deviation unacceptable’ (>0.03 cc of PTV receiving <91% of prescription) and 12 had
‘variation acceptable’ (>0.03 cc of PTV receiving 91-93% of prescription) scores for the
tumor dose-volume analysis, due to the minimum dose requirements. For normal tissues,
only one ‘deviation unacceptable’ was recorded for small bowel and no ‘deviation
unacceptable’ cases were noted for bladder, rectum or femoral heads, though 12 patients had
acceptable variations for the dose-volume analysis recorded (Table 2).
Primary Endpoint

Author Manuscript

Acute Adverse Events—Of the 30 patients, 7 (23.3%, 95% CI: 10.6%-36.0%) developed
grade ≥3, treatment-related, non-hematologic AEs ≤90 days from the start of concurrent
treatment (i.e., acute AEs). Table 3a lists the grade 3 and 4 side effects, including
hematologic toxicity, in detail. As the one-sided, upper-bound confidence interval for the
rate of grade ≥3, treatment-related, nonhematologic AEs occurring ≤90 days from the start
of concurrent treatment is 36%, there is 95% confidence that the true grade ≥3, nonhematologic, treatment-related AE rate is not greater than 60%. One acute toxicity, a
thromboembolic event, was considered possibly attributable to Bev.
Secondary Endpoints
Late Adverse Events—Treatment-related grade ≥3 AEs occurring >90 days but ≤365
days from the start of concurrent treatment are listed in Table 3b. Nine patients reported late
AEs, three of whom also had acute toxicities.
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AEs occurring during concurrent treatment, adjuvant chemotherapy treatment, and after the
end of all treatment are shown in Table 4. One late toxicity, epistaxis, was considered
possibly attributable to Bev.
Survival outcomes—The median follow-up time for all patients was 25.9 months (minmax: 13.6-43.4). The 2-year estimate of OS was 96.7% (95% CI: 78.6%-99.5%) with a total
of 4 deaths, all from endometrial cancer. None of the 30 patients enrolled had a within-field
pelvic-only failure. The cumulative incidences for RF and DF at 2 years were 7.2% (95%
Cancer. Author manuscript; available in PMC 2016 July 01.
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CI: 0.0%-17.1%) and 17% (95% CI: 3.2%-30.9%), respectively. The 2-year estimate of DFS
was 79.1% (95% CI: 59.2%-90.1%). A total of 6 patients had recurrent disease. Two of the 6
had para-aortic nodal failures; one of these also had distant-nodal metastases, and both
subsequently died. One of the two patients with para-aortic nodal failure had undergone a
para-aortic lymph node dissection at diagnosis; both had undergone pelvic node
lymphadenectomy at diagnosis. Two of the other four patients died of distant disease. The
remaining two patients were alive with distant failure at the time of this analysis; one
remains on chemotherapy and the other had a 1-cm recurrence in the peritoneum above the
pelvic field at a laparoscopic port site, which was resected laparoscopically with negative
margins. She remains on megestrol acetate and has been disease free for 2 years. Detailed
characteristics of the patients with recurrence are shown in Table 5.

DISCUSSION
Author Manuscript

This phase II prospective trial demonstrates the feasibility of administering bevacizumab
(Bev) with pelvic intensity modulated radiation therapy (IMRT) followed by carboplatin/
paclitaxel chemotherapy in high-risk endometrial cancer. The rate of acute grade >3, nonhematologic, treatment-related toxicity was 23.3% and the hypothesis that the true rate of
such AEs is not greater than 60% was confirmed. This treatment regimen is feasible with
few Bev-related toxicities. A total of 93% of patients were treated per protocol with
concurrent chemotherapy and 90% received their adjuvant chemotherapy per protocol. All
patients received Bev in full and on time. Compared to RTOG 9708, changes in this trial
include adding Bev to concurrent cisplatin-based chemoradiation, switching from cisplatin/
paclitaxel to carboplatin/paclitaxel after concurrent chemoradiation, and using IMRT instead
of 3D conformal radiation.

Author Manuscript

In this RTOG 0921 trial of concurrent Bev, cisplatin and radiation, one acute toxicity, a
thromboembolic event, and one late toxicity, epistaxis, were considered possibly attributable
to Bev. Therefore, this study uniquely finds that Bev may be administered during pelvic
radiation to the post-operative pelvis without increasing pelvic complications. There were no
side effects attributable to the use of carboplatin instead of cisplatin in conjunction with
paclitaxel. The use of adjuvant chemotherapy in comparison to radiation in highintermediate or advanced-stage endometrial-cancer patients has been reported in three
randomized trials; none used carboplatin/paclitaxel.

Author Manuscript

Other studies have shown an effect of Bev in endometrial cancer. One study treated patients
with recurrent disease definitively to a local field with concurrent radiation and Bev 10
mg/m2 every 2 weeks for 3 doses; no other chemotherapy was administered.9 Results
showed 2 out of 19 patients had thromboembolic events, 2 patients had grade 1 and 3
patients had grade 2 proteinuria, 2 patients had grade 1 and 2 patients had grade 2
hypertension, and 1 patient had a grade 1 nosebleed. Dramatic shrinkage of the tumor was
noted for patients with recurrent endometrial cancer, with a 3-year overall survival rate of
80%. Another study analyzed data from patients with persistent or recurrent endometrial
cancer treated with Bev 15 mg/kg every 3 weeks until disease progression or prohibitive
toxicity without other chemotherapy.10 The authors reported an overall response rate of
13.5%, a median progression-free survival of 4 months and a median overall survival time
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of 10 months. In comparison, in the current study, patients were treated immediately
postoperatively rather than at the time of recurrence, and they received a dose of 5mg/kg in
order to minimize side effects related to Bev.

Author Manuscript

Chemotherapy has been variously compared to radiation and combined with it. In trials
comparing the two modalities, the chemotherapy-alone arms demonstrate local relapse rates
of 18% for women with stage III-IV disease2 and 11%11 or 7%12 for those with stage ICIIIC disease. Chemotherapy is thought to confer a survival advantage when combined with
radiation.13 For patients with high-intermediate and advanced disease, a combination of
chemotherapy and radiation offers potential reductions in both local and distant relapses.
The GOG 0184 trial randomized patients treated with surgery and pelvic and/or para-aortic
radiation to cisplatin and doxorubicin with or without paclitaxel; 10% had a local-regional
recurrence and 30% had distant recurrence.14 RTOG 9708, a phase II trial of concurrent
cisplatin with radiation and 4 cycles of cisplatin (50 mg/m2) and paclitaxel (175 mg/m2
every 4 weeks) after radiation, showed a 4-year pelvic recurrence rate of 2%, a regional
recurrence rate of 2% and a distant recurrence rate of 19%.4 No recurrences occurred in the
13 stage IC, IIA, or IIB patients.15 In terms of clinical outcomes, at 2 years, RTOG 9708 had
a 2-year overall survival rate of 91% compared to this study at 97%, however continued
follow-up is required for more complete conclusions. These studies indicate the efficacy of
combined chemo-radiation at improving local control, but demonstrate the need for novel
agents to reduce the rate of distant relapse. This trial was administered to patients with
performance status 0-1; it is not clear whether patients with worse performance status would
tolerate the addition of bevacizumab and chemotherapy.

Author Manuscript

IMRT treats regions at risk for disease spread while sparing adjacent normal tissues. IMRT
may reduce the dose to normal tissues, thereby potentially decreasing acute and chronic
toxicity.16,17 Retrospective studies of pelvic IMRT indicate that the volume of small bowel
treated to more than 45 Gy is smaller with IMRT than with whole-pelvic radiation.
Portelance et al. showed a >60% reduction in the volume of small bowel irradiated to more
than 45 Gy with IMRT.18 A study by Roeske and colleagues showed a 50% reduction in the
volume of small bowel irradiated to more than 45 Gy.19

Author Manuscript

Overall, the grade 3 or higher toxicity rate reported during concurrent treatment in RTOG
9708 (3D conformal pelvic radiation and concurrent cisplatin chemotherapy followed by
adjuvant cisplatin and paclitaxel) was 30%. To determine whether IMRT may be of benefit
in reducing this rate, toxicities during radiation in the current study (RTOG 0921) were
compared to those of the precursor trial RTOG 9708. In RTOG 9708, during the concurrent
portion of the treatment, 43% of participants had grade 2, 27% had grade 3, and 2% had
grade 4 acute toxicity; in this RTOG 0921 trial, these rates were 30%, 23% and 7%,
respectively. Of note, though the systems are similar, toxicity in RTOG 9708 was assessed
according to the Cooperative Group Common Toxicity Criteria 1989, the Acute Radiation
Morbidity Scoring Criteria, and the Late Radiation Morbidity Scoring Scheme of the RTOG
and the European Organization for Research and Treatment of Cancer, whereas the current
trial used the subsequent CTCAE version 4.0 which developed from the preceding scales.
Prospective results from the ongoing RTOG 1203 TIME-C randomized trial may help to
clarify whether IMRT reduces toxicity compared to 3D conformal radiation.

Cancer. Author manuscript; available in PMC 2016 July 01.
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Relative to RTOG 0418, a prospective series of patients treated with postoperative pelvic
IMRT, the less strict dose-volume histogram criteria used in the current trial resulted in
higher compliance for constraints. In RTOG 0418, dose criteria were not met in 67% of
cases for bladder, in 76% for rectum, and in 17% for small bowel. In comparison, in the
current trial, dose criteria were not met in 14% (4/29) of cases for bladder, in 24% (7/29) for
rectum, and in 14% (4/28) for bowel. To illustrate the effect of stringency, the femoral head
constraint in RTOG 0921 was met in all cases (all had DVH value of 15% receiving < 35
Gy); in contrast, the RTOG 0418 constraint was not met in 33% of cases (<15% of the
femoral heads receiving ≥30 Gy). No increase in toxicity was noted with the less stringent
constraints. The high number of variations in PTV calculations indicates the need for
relaxation of these constraints in future trials.
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In conclusion, treating endometrial-cancer patients with concurrent bevacizumab, cisplatin
and pelvic radiation followed by carboplatin/paclitaxel chemotherapy is feasible, has low
rates of bevacizumab-specific toxicities and a high survival rate at 2 years. Future
randomized trials should further address the use of bevacizumab in endometrial cancer.
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Table 1

Author Manuscript

Baseline characteristics (n=30)
Age (years)
    Median (min-max)

59 (34 – 80)

Hysterectomy procedure
    Robotic-assisted vaginal hysterectomy

30% (9)

    Total abdominal hysterectomy

23.3% (7)

    Radical hysterectomy

23.3% (7)

    Laparoscopic-assisted vaginal hysterectomy

23.3% (7)

Pelvic lymph node removal
    Yes

96.7% (29)

    No

3.3% (1)

Para-aortic lymph node removal

Author Manuscript

    Yes

63.3% (19)

    No

36.7% (11)

Histologic type
    Endometrioid endometrial adenocarcinoma

60% (18)

    Papillary serous adenocarcinoma

30% (9)

    Clear cell carcinoma

10% (3)

Stages
    Papillary serous or clear cell adenocarcinoma:
        I

16.7% (5)

        II

13.3% (4)

        IIIC1

10% (3)

    Endometrioid endometrial adenocarcinoma:

Author Manuscript

        II
        IIIA
        IIIB
        IIIC1

6.7% (2)
16.7% (5)
3.3% (1)
33.3% (10)
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Table 2

Author Manuscript

Tumor and Normal-Tissue Dose-Volume Analysis Criteria and Score Statistics
Structure

Per Protocol

Variation Acceptable

Deviation Unacceptable

PTV

≥0.03 cc of PTV
with ≥93% of
prescribed dose

43% (13)

≥0.03 cc of PTV
with 91-<93% of
prescribed dose

40% (12)

≥0.03 cc of PTV with
<91% of prescribed dose

17% (5)

Small bowel (missing,
n=2)

30% receives <40
Gy

86% (24)

30% receives >40<45 Gy

11% (3)

>30% receives >45 Gy and
≥0.03 cc .receives >65 Gy

4% (1)

Rectum (missing, n=1)

60% receives ≤40
Gy

76% (22)

60% receives 40-<
45 Gy

24% (7)

>60% receives >45 Gy and
≥0.03 cc receives >65 Gy

0% (0)

Bladder (missing, n=1)

35% receives ≤45
Gy

86% (25)

35% receives 45<50 Gy

14% (4)

>35% receives >50 Gy and
≥0.03 cc receives >65 Gy

0% (0)

Femoral heads

15% receives <35
Gy

100% (30)

>15% - ≤50%
receives >35 Gy

0% (0)

>50% receives >35 Gy and
≥0.03 cc receives >65 Gy

0% (0)

Key: Rx=prescription; Gy = Gray, PTV = planning target volume

Author Manuscript
Author Manuscript
Author Manuscript
Cancer. Author manuscript; available in PMC 2016 July 01.

Viswanathan et al.

Page 12

Table 3a

Author Manuscript

a. Adverse events ≥ grade 3 in the first 90 days from the start of concurrent treatment (acute)
System Organ Class

Term

Grade

Relationship to Treatment

Days from
Concurrent RX
start

Nervous system disorders

Headache

3

Probable

78

General disorders and administration
site conditions

Fatigue

3

Probable

85

Nervous system disorders

Syncope

3

Possible

89

4

Probable

42

Hyponatremia

3

Probable

55

Hyperglycemia

3

Possible

90

Infections and infestations

Vaginal infection

3

Probable

28

Reproductive system and breast
disorders

Vaginal inflammation

3

Possible

27

Investigations

Alanine aminotransferase increased

3

Possible

12

Blood and lymphatic system disorders

Febrile neutropenia

4

Probable

88

General disorders and administration
site conditions

Fatigue

3

Possible

4

*

Vascular disorders

Thromboembolic event

Metabolism and nutrition disorders

Author Manuscript
Author Manuscript
Author Manuscript
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Table 3b

Author Manuscript

b. Adverse events ≥ grade 3 occurring >90 days but ≤365 from the start of concurrent treatment (late)
System Organ Class

Term

Grade

Relationship to Treatment

Days from Concurrent
RX start

General disorders and administration site conditions

Fatigue

3

Probable

105

Metabolism and nutrition disorders

Hypomagnesemia

4

Possible

183

Hypokalemia

3

Possible

168

*

3

Probable

176

Nervous system disorders

Headache

3

Probable

98

Metabolism and nutrition disorders

Hyponatremia

3

Possible

98

Vascular disorders

Hot flashes

3

Definite

300

General disorders and administration site conditions

Pain

3

Possible

180

Ear and labyrinth disorders

Hearing impaired

3

Probable

333

Metabolism and nutrition disorders

Hypokalemia

4

Probable

136

Nervous system disorders

Neuralgia

3

Possible

126

Infections and infestations

Skin infection

3

Possible

126

Respiratory, thoracic and mediastinal disorders

Epistaxis

Author Manuscript

Key: RX=treatment
*

probably attributable to bevacizumab
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Table 4

Author Manuscript

Summary of Worst Adverse Event per Patient (definitely, probably, or possibly related to treatment)
comparing RTOG 9708 with RTOG 0921
AEs ≤90 days
from the start
1
of all RX

AEs >90 days from the start of all
2
RX

AEs occurring during
3
concurrent RX

AEs occurring during adjuvant
4
chemo

RTOG 0921

RTOG 0921

RTOG 9708

RTOG 0921

RTOG 9708

RTOG 0921

RTOG 9708

1

0 ( 0%)

3 (10%)

9 (20%)

1 ( 3%)

12 (27%)

0 ( 0%)

3 ( 7%)

2

10 (33%)

10 (33%)

17 (39%)

9 (30%)

19 (43%)

6 (20%)

3 ( 7%)

3

11 (37%)

9 (30%)

7 (16%)

7 (23%)

12 (27%)

12 (40%)

9 (21%)

4

5 (17%)

6 (20%)

1 ( 2%)

2 ( 7%)

1 ( 2%)

6 (20%)

26 (62%)

5

0 ( 0%)

0 ( 0%)

0 ( 0%)

0 ( 0%)

0 ( 0%)

0 ( 0%)

0 ( 0%)

Grade

Key: RX=treatment

Author Manuscript

1

AE date ≤ (start of all treatment +90 days)

2

AE date > (start of all treatment +90 days)

3

Concurrent treatment start date ≤ AE date ≤ concurrent treatment end date

4

Adjuvant treatment start date ≤ AE date ≤ adjuvant treatment end date
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Table 5

Author Manuscript

Characteristics of patients with relapsed disease
Patient

Stage

Histology

First recurrence

Areas of spread

Time from first recurrence to death (months)

1

IIIC1

UPSC

Regional

Para-aortic node

10

2

IIIC1

UPSC

Regional

Para-aortic node

4

3

IIIC1G2

EAC

Distant

Lung, bone, brain

8

4

IIIC1G3

EAC

Distant

Lung

6

5

IIIBG3

EAC

Distant

Lung

Alive

6

IIIAG1

EAC

Distant

Abdominal

Alive

Key: EAC= Endometrioid endometrial adenocarcinoma; CC=Clear cell carcinoma; UPSC=Papillary serous adenocarcinoma
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